Comparison of BCVA values for TCG patients.
Version 1Background Timely anti-vascular endothelial growth factor (VEGF) therapy is essential for visual function in neovascular age-related macular degeneration (nAMD). The coronavirus pandemic has led to unprecedented delays in anti-VEGF intravitreal therapy because of the need to reduce hospital attendance. Objectives To assess the long-term impact of COVID-19 pandemic-related delays in intravitreal anti-VEGF therapy on nAMD patients. Methods This was a retrospective study of 98 patients (102 eyes)
No license available
Background Timely anti-vascular endothelial growth factor (VEGF) therapy is essential for visual function in neovascular age-related macular degeneration (nAMD). The coronavirus pandemic has led to unprecedented delays in anti-VEGF intravitreal therapy because of the need to reduce hospital attendance. Objectives To assess the long-term impact of COVID-19 pandemic-related delays in intravitreal anti-VEGF therapy on nAMD patients. Methods This was a retrospective study of 98 patients (102 eyes)